{
    "clinical_study": {
        "@rank": "78848", 
        "arm_group": [
            {
                "arm_group_label": "Ergoferon (1 tablet 3 times a day)", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID."
            }, 
            {
                "arm_group_label": "Oseltamivir(Tamiflu): 75 mg two times a day.", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is:\n\n        -  to assess clinical efficiency of Ergoferon for treatment of influenza\n\n        -  to assess safety of Ergoferon for treatment of influenza\n\n        -  to compare efficiency of Ergoferon and Tamiflu for treatment of influenza"
        }, 
        "brief_title": "Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients of both sexes aged from 18 to 60 inclusively.\n\n          2. Patients with body temperature >37,8\u00b0C at the moment of examination by the doctor;\n             with at least one catarrh symptom (cough, rhinitis, sore throat) and one intoxication\n             symptom (myalgia, fever/hyperhidrosis, malaise, weakness, headache) during seasonal\n             influenza morbidity.\n\n          3. Diagnosed influenza confirmed by express diagnostics (presence of antigens of\n             influenza virus in nasal passages epithelium and proved by QuickVue immunological\n             test).\n\n          4. The possibility to start therapy within 24 hours after the onset of the first\n             influenza symptoms.\n\n          5. Signed Informed Consent form for participation in the study.\n\n        Exclusion Criteria:\n\n          1. Patients aged below 18 years and above 60 years.\n\n          2. Suspected invasive bacterial infection or presence of severe disease requiring use of\n             antibacterial drugs (including sulfanilamides).\n\n          3. Vaccination against influenza prior to epidemic season onset.\n\n          4. Medical history of polyvalent allergy.\n\n          5. Allergy/ intolerance to any of the components of  medications used in the treatment.\n\n          6. Exacerbation or decompensation of chronic diseases affecting the patient's ability to\n             participate in the clinical trial.\n\n          7. Chronic renal insufficiency.\n\n          8. Intake of medicines listed in the section \"Prohibited concomitant treatment\" for  15\n             days prior to the inclusion in the trial.\n\n          9. Pregnancy, breast feeding, unwillingness to keeping to contraception method during\n             the study.\n\n         10. Drug addiction,  alcohol usage in the amount over 2 units of alcohol per day.\n\n         11. Patients, who from investigator's point o view, will fail to comply with the\n             observation requirements of the trial or with the intake regimen of the investigated\n             medicines.\n\n         12. Participation in other clinical trials in the course of 1 month prior to the\n             inclusion in the trial.\n\n         13. The patient is related to the research personnel of the investigative site, who are\n             directly involved in the trial or are the immediate relative of the reseacher. The\n             immediate relatives includes husband / wife, parents, children, brothers (or\n             sisters), regardless of whether they are natural or adopted.\n\n         14. The patient works for OOO \"NPF \"Materia Medica Holding\" (i.e. is the company's\n             employee, temporary contract worker or designated official responsible for carrying\n             out the research) or the immediate relative."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "370", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804946", 
            "org_study_id": "MMH-ER-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ergoferon (1 tablet 3 times a day)", 
                "description": "Safety and Efficiency of Ergoferon in treatment of Influenza", 
                "intervention_name": "Ergoferon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Oseltamivir(Tamiflu): 75 mg two times a day.", 
                "description": "Safety and Efficiency in treatment of Influenza", 
                "intervention_name": "Oseltamivir(Tamiflu)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oseltamivir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "125212"
                    }, 
                    "name": "Federal Budgetary Institution of Science \"Moscow Scientific Research Institute of Epidemiology and Microbiology named after G.N. Gabrichevskiy\" of Federal Service on Surveillance in Consumers Protection and Welfare"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "105064"
                    }, 
                    "name": "Federal State Budgetary Institution \"Scientific Research Institute for Vaccines and Serum named after I.I.Mechnikov\" of Russian Academy of Medical Science"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "129090"
                    }, 
                    "name": "Federal State Budgetary Institution \"Polyclinic \u2116 3\" of Affairs Management Department of the President of Russian Federation"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117997"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education \"The Russian National Research Medical University named after N.I. Pirogov\" of Ministry of Health and Social Development of Russian Federation"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115682"
                    }, 
                    "name": "Federal State Health Care Institution \"Clinical Hospital \u211683\" of Federal Biomedical Agency"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Podolsk", 
                        "country": "Russian Federation", 
                        "zip": "142105"
                    }, 
                    "name": "Municipal Health Care Institution \"Podolsk City Clinical Hospital \u21163\""
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation", 
                        "zip": "214019"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education \"Smolensk State Medical Academy\" of Ministry of Health and Social Development of Russian Federation"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "last_name": "Diana Alpenidze"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "St. Petersburg State Budgetary Health Care Institution \"\u0421ity Polyclinic \u2116 117\""
                }, 
                "investigator": {
                    "last_name": "Diana Alpenidze", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194044"
                    }, 
                    "name": "Federal State Budgetary Health Care Institution \"All-Russian center for Emergency and Radiological Medicine named after A.M. Nikiforov\" of Ministry of Russian Federation on Civil Defence, Emergencies and Relief of the Consequencies of Natural Disasters"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "last_name": "Danila Chijov"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "198328"
                    }, 
                    "name": "St. Petersburg State Budgetary Health Care Institution \"City Polyclinic \u2116106\""
                }, 
                "investigator": {
                    "last_name": "Danila Chijov", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vladimir", 
                        "country": "Russian Federation", 
                        "zip": "600023"
                    }, 
                    "name": "State Budgetary Health Care Institution of the Vladimir Region \"Regional Clinical Hospital\""
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voronezh", 
                        "country": "Russian Federation", 
                        "zip": "394036"
                    }, 
                    "name": "State Educational Institution of Higher Professional Education \"Voronezh State Academy named after N.N. Burdenko\" of Ministry of Health and Social Development of Russian Federation"
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation", 
                        "zip": "150000"
                    }, 
                    "name": "State Budgetary Educational Institution of Higher Professional Education \"Yaroslavl State Medical Academy\" of Ministry of Health and Social Development of Russian Federation"
                }, 
                "status": "Terminated"
            }
        ], 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza", 
        "other_outcome": {
            "measure": "Intensity of influenza clinical manifestations (body temperature, intoxication signs, catarrh symptoms in scores)", 
            "safety_issue": "No", 
            "time_frame": "on days 1, 3 and 7 of the observation"
        }, 
        "overall_contact": {
            "email": "PutilovskiyMA@materiamedica.ru", 
            "last_name": "Mikhail Putilovskiy, MD", 
            "phone": "+74957836804", 
            "phone_ext": "302"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients whose body temperature normalized (no more than 37.0\u00ba\u0421)", 
            "safety_issue": "No", 
            "time_frame": "up to 5 days of the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Proportion of patients whose influenza clinical manifestations were arrested", 
            "safety_issue": "No", 
            "time_frame": "on the day 7 of the observation"
        }, 
        "source": "Materia Medica Holding", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Materia Medica Holding", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}